EQT FUND MANAGEMENT S A R L
Q3 2026 Form 13-F
LUXEMBOURG
CIK 0001834239
· CRD 288390
· Exempt reporting adviser
$947.4M Reported Value Total
Exempt Reporting Adviser
Source: Form ADV filed 2026-03-30
Reported value
$947.4M
Quarter over quarter
+4.9%
Holdings
6
Top-10 concentration
100.0%
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Peter Veldman
Manager
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 12, 2026 |
| Form | 13F-HR |
| Reported value | $947.4M |
| Positions | 6 |
| Change in reported value | +9.8% |
| New positions | 1 |
| Exited positions | 0 |
| Position turnover | 16.7% |
| Top-10 concentration | 100.0% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
6 | $947.4M |
|
Q2 2026 13F
Filed Aug 13, 2026
|
5 | $862.6M |
|
Q1 2026 13F
Filed May 14, 2026
|
5 | $1.0B |
|
Q4 2025 13F
Filed Feb 11, 2026
|
4 | $1.1B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
4 | $1.9B |
|
Q3 2023 13F
Filed Oct 30, 2023
|
0 | $0 |
|
Q2 2023 13F
Filed Aug 9, 2023
|
0 | $0 |
|
Q1 2023 13F
Filed Apr 19, 2023
|
0 | $0 |
|
Q4 2022 13F
Filed Feb 6, 2023
|
0 | $0 |
|
Q3 2022 13F
Filed Nov 14, 2022
|
2 | $399.0M |
|
Q2 2022 13F
Filed Jul 21, 2022
|
2 | $775.0M |
Top 6 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | WAY WAYSTAR HLDG CORP | $630.4M | 66.54% |
| 2 | PHVS PHARVARIS N V | $108.6M | 11.47% |
| 3 | OCS OCULIS HOLDING AG | $64.9M | 6.85% |
| 4 | AGMB AGOMAB THERAPEUTICS NV | $57.1M | 6.02% |
| 5 | EVMN EVOMMUNE INC | $43.7M | 4.61% |
| 6 | ETRA ELECTRA THERAPEUTICS INC | $42.7M | 4.51% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.